Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NOTA-Nectin-4 antibody fragment
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**68Ga-NOTA-Nectin-4 antibody fragment** is a radiopharmaceutical agent consisting of an antibody fragment (such as F(ab')2 or single-chain variable fragment/scFv) that targets nectin-4, a cell adhesion molecule overexpressed in multiple malignancies including urothelial carcinoma, breast cancer, and non-small cell lung cancer. The fragment is conjugated to the NOTA chelator and labeled with the positron-emitting isotope gallium-68 (^68Ga) for positron emission tomography (PET) imaging. The mechanism of action involves highly specific binding to nectin-4 on tumor cells, enabling visualization and quantification of nectin-4 expression in vivo through PET imaging. This targeted imaging approach is designed to support personalized oncology, including patient selection and response prediction for nectin-4-targeted therapies.
- Other names
- 68Ga-NOTA-Nectin-4 F(ab')268Ga-NOTA-Nectin-4 scFv
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)
Beyond the preview
Go deeper on 68Ga-NOTA-Nectin-4 antibody fragment.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-NOTA-Nectin-4 antibody fragment.